175 related articles for article (PubMed ID: 15582984)
1. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
Jahrsdörfer B; Wooldridge JE; Blackwell SE; Taylor CM; Griffith TS; Link BK; Weiner GJ
J Leukoc Biol; 2005 Mar; 77(3):378-87. PubMed ID: 15582984
[TBL] [Abstract][Full Text] [Related]
2. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
[TBL] [Abstract][Full Text] [Related]
3. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
[TBL] [Abstract][Full Text] [Related]
4. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
Zhang Z; Guo K; Schluesener HJ
J Neuroimmunol; 2005 Apr; 161(1-2):68-77. PubMed ID: 15748945
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
6. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
Jahrsdorfer B; Mühlenhoff L; Blackwell SE; Wagner M; Poeck H; Hartmann E; Jox R; Giese T; Emmerich B; Endres S; Weiner GJ; Hartmann G
Clin Cancer Res; 2005 Feb; 11(4):1490-9. PubMed ID: 15746051
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
[TBL] [Abstract][Full Text] [Related]
8. Differences in constitutive and activation-induced expression of CD69 and CD95 between normal and chronic lymphocytic leukemia B cells.
De Fanis U; Romano C; Dalla Mora L; Sellitto A; Guastafierro S; Tirelli A; Bresciano E; Giunta R; Lucivero G
Oncol Rep; 2003; 10(3):653-8. PubMed ID: 12684639
[TBL] [Abstract][Full Text] [Related]
9. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
Gantner F; Hermann P; Nakashima K; Matsukawa S; Sakai K; Bacon KB
Eur J Immunol; 2003 Jun; 33(6):1576-85. PubMed ID: 12778475
[TBL] [Abstract][Full Text] [Related]
10. Immunostimulatory CpG-oligodeoxynucleotides (CpG-ODN) induce early hepatic injury, but provide a late window for protection against endotoxin-mediated liver damage.
Slotta JE; Scheuer C; Menger MD; Vollmar B
J Hepatol; 2006 Mar; 44(3):576-85. PubMed ID: 16310279
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.
Liang X; Moseman EA; Farrar MA; Bachanova V; Weisdorf DJ; Blazar BR; Chen W
Blood; 2010 Jun; 115(24):5041-52. PubMed ID: 20339095
[TBL] [Abstract][Full Text] [Related]
12. Oligonucleotide IMT504 induces an immunogenic phenotype and apoptosis in chronic lymphocytic leukemia cells.
Rodriguez JM; Elias F; Montaner A; Flo J; Lopez RA; Zorzopulos J; Franco RJ; Lenial SP; Lopez Salón M; Pirpignani ML; Solimano J; Garay G; Riveros D; Fernandez J; Cacchione R; Dupont J
Medicina (B Aires); 2006; 66(1):9-16. PubMed ID: 16555722
[TBL] [Abstract][Full Text] [Related]
13. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.
Longo PG; Laurenti L; Gobessi S; Petlickovski A; Pelosi M; Chiusolo P; Sica S; Leone G; Efremov DG
Leukemia; 2007 Jan; 21(1):110-20. PubMed ID: 17024114
[TBL] [Abstract][Full Text] [Related]
14. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia.
Loeder S; Zenz T; Schnaiter A; Mertens D; Winkler D; Döhner H; Debatin KM; Stilgenbauer S; Fulda S
Cancer Res; 2009 Dec; 69(23):8977-86. PubMed ID: 19920200
[TBL] [Abstract][Full Text] [Related]
15. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
Inoue S; MacFarlane M; Harper N; Wheat LM; Dyer MJ; Cohen GM
Cell Death Differ; 2004 Dec; 11 Suppl 2():S193-206. PubMed ID: 15608694
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
[TBL] [Abstract][Full Text] [Related]
18. Interaction of CpG-oligodeoxynucleotides with Toll like receptor 9 induces apoptosis and modulates metaloproteinase-2 activity in human intestinal epithelium.
Khorramizadeh MR; Hosseinzadeh S; Safavifar F; Saadat F; Aalizadeh N; Falak R; Jadali Z; Pezeshki M
Iran J Allergy Asthma Immunol; 2007 Sep; 6(3):107-14. PubMed ID: 17893430
[TBL] [Abstract][Full Text] [Related]
19. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.
Vollmer J; Weeratna R; Payette P; Jurk M; Schetter C; Laucht M; Wader T; Tluk S; Liu M; Davis HL; Krieg AM
Eur J Immunol; 2004 Jan; 34(1):251-62. PubMed ID: 14971051
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
